Geron Corporation (0IV3.L)
USD 1.36
(-8.26%)
USD 1.36
(-8.26%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 14.76 Million USD | 1113.8% |
| 2022 | -1.45 Million USD | -107.23% |
| 2021 | 20.12 Million USD | 3.58% |
| 2020 | 19.43 Million USD | 271.05% |
| 2019 | -11.36 Million USD | -4.76% |
| 2018 | -10.84 Million USD | 34.69% |
| 2017 | -16.6 Million USD | -26.95% |
| 2016 | -13.07 Million USD | 39.21% |
| 2015 | -21.51 Million USD | 50.04% |
| 2014 | -43.06 Million USD | -231.5% |
| 2013 | -12.99 Million USD | 43.17% |
| 2012 | -22.85 Million USD | -41.92% |
| 2011 | -16.1 Million USD | 65.56% |
| 2010 | -46.76 Million USD | -32.13% |
| 2009 | -35.39 Million USD | 67.63% |
| 2008 | -109.34 Million USD | 25.12% |
| 2007 | -146.02 Million USD | -7.46% |
| 2006 | -135.88 Million USD | -40.7% |
| 2005 | -96.57 Million USD | -1363.08% |
| 2004 | -6.6 Million USD | 0.47% |
| 2003 | -6.63 Million USD | -130.96% |
| 2002 | 21.41 Million USD | 1681.91% |
| 2001 | -1.35 Million USD | -140.13% |
| 2000 | 3.37 Million USD | -67.87% |
| 1999 | 10.5 Million USD | 241.89% |
| 1998 | -7.4 Million USD | -311.11% |
| 1997 | -1.8 Million USD | 81.25% |
| 1996 | -9.6 Million USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | -104.35 Million USD | -806.94% |
| 2024 Q2 | -31.02 Million USD | 70.27% |
| 2023 Q1 | -57.3 Million USD | -3835.44% |
| 2023 Q4 | 14.76 Million USD | -41.68% |
| 2023 Q3 | 25.31 Million USD | 2696.0% |
| 2023 FY | 14.76 Million USD | 1113.8% |
| 2023 Q2 | -975 Thousand USD | 98.3% |
| 2022 FY | -1.45 Million USD | -107.23% |
| 2022 Q4 | -1.45 Million USD | 75.59% |
| 2022 Q1 | 23.88 Million USD | 18.68% |
| 2022 Q2 | -20.74 Million USD | -186.86% |
| 2022 Q3 | -5.96 Million USD | 71.25% |
| 2021 Q4 | 20.12 Million USD | 84.09% |
| 2021 FY | 20.12 Million USD | 3.58% |
| 2021 Q1 | -1.76 Million USD | -109.06% |
| 2021 Q2 | -17.43 Million USD | -890.74% |
| 2021 Q3 | 10.93 Million USD | 162.7% |
| 2020 FY | 19.43 Million USD | 271.05% |
| 2020 Q4 | 19.43 Million USD | 227.19% |
| 2020 Q1 | -14.57 Million USD | -28.32% |
| 2020 Q2 | -17.01 Million USD | -16.75% |
| 2020 Q3 | -15.27 Million USD | 10.23% |
| 2019 Q4 | -11.36 Million USD | 44.32% |
| 2019 FY | -11.36 Million USD | -4.76% |
| 2019 Q1 | -6.22 Million USD | 42.56% |
| 2019 Q2 | -17.3 Million USD | -177.86% |
| 2019 Q3 | -20.4 Million USD | -17.88% |
| 2018 Q4 | -10.84 Million USD | 14.81% |
| 2018 FY | -10.84 Million USD | 34.69% |
| 2018 Q3 | -12.72 Million USD | 33.45% |
| 2018 Q2 | -19.12 Million USD | -141.75% |
| 2018 Q1 | -7.91 Million USD | 52.35% |
| 2017 Q3 | -9.9 Million USD | -49.92% |
| 2017 Q4 | -16.6 Million USD | -67.64% |
| 2017 FY | -16.6 Million USD | -26.95% |
| 2017 Q1 | -14.86 Million USD | -13.63% |
| 2017 Q2 | -6.6 Million USD | 55.55% |
| 2016 Q2 | -8.19 Million USD | 35.96% |
| 2016 Q4 | -13.07 Million USD | -122.3% |
| 2016 Q1 | -12.8 Million USD | 40.5% |
| 2016 Q3 | -5.88 Million USD | 28.25% |
| 2016 FY | -13.07 Million USD | 39.21% |
| 2015 Q1 | -10.44 Million USD | 75.74% |
| 2015 Q4 | -21.51 Million USD | -27.89% |
| 2015 FY | -21.51 Million USD | 50.04% |
| 2015 Q3 | -16.82 Million USD | -6.49% |
| 2015 Q2 | -15.79 Million USD | -51.21% |
| 2014 Q1 | -11.32 Million USD | 12.83% |
| 2014 FY | -43.06 Million USD | -231.5% |
| 2014 Q2 | -9.52 Million USD | 15.93% |
| 2014 Q4 | -43.06 Million USD | -447.51% |
| 2014 Q3 | -7.86 Million USD | 17.38% |
| 2013 Q4 | -12.99 Million USD | -35.44% |
| 2013 Q1 | -16.29 Million USD | 28.69% |
| 2013 FY | -12.99 Million USD | 43.17% |
| 2013 Q2 | -8.83 Million USD | 45.8% |
| 2013 Q3 | -9.59 Million USD | -8.57% |
| 2012 FY | -22.85 Million USD | -41.92% |
| 2012 Q4 | -22.85 Million USD | -36.04% |
| 2012 Q3 | -16.8 Million USD | -12.64% |
| 2012 Q2 | -14.91 Million USD | 24.75% |
| 2012 Q1 | -19.82 Million USD | -23.09% |
| 2011 FY | -16.1 Million USD | 65.56% |
| 2011 Q1 | -36.2 Million USD | 21.25% |
| 2011 Q2 | -32.81 Million USD | 9.37% |
| 2011 Q3 | -30.78 Million USD | 6.19% |
| 2011 Q4 | -16.1 Million USD | 47.68% |
| 2010 Q1 | -36.69 Million USD | -6.04% |
| 2010 FY | -46.76 Million USD | -32.13% |
| 2010 Q4 | -45.97 Million USD | -30.3% |
| 2010 Q3 | -35.28 Million USD | 7.41% |
| 2010 Q2 | -38.1 Million USD | -3.86% |
| 2009 Q2 | -101.37 Million USD | 19.29% |
| 2009 FY | -35.39 Million USD | 67.63% |
| 2009 Q4 | -34.6 Million USD | 64.93% |
| 2009 Q3 | -98.66 Million USD | 2.67% |
| 2009 Q1 | -125.6 Million USD | -14.86% |
| 2008 Q4 | -109.34 Million USD | 10.23% |
| 2008 FY | -109.34 Million USD | 25.12% |
| 2008 Q1 | -138.67 Million USD | 5.04% |
| 2008 Q2 | -127.08 Million USD | 8.36% |
| 2008 Q3 | -121.8 Million USD | 4.15% |
| 2007 FY | -146.02 Million USD | -7.46% |
| 2007 Q4 | -146.02 Million USD | 4.41% |
| 2007 Q3 | -152.76 Million USD | -21.18% |
| 2007 Q2 | -126.06 Million USD | 13.49% |
| 2007 Q1 | -145.72 Million USD | -7.24% |
| 2006 Q4 | -135.88 Million USD | -29.96% |
| 2006 Q3 | -104.55 Million USD | -51.81% |
| 2006 FY | -135.88 Million USD | -40.7% |
| 2006 Q1 | -80.37 Million USD | 16.78% |
| 2006 Q2 | -68.87 Million USD | 14.31% |
| 2005 FY | -96.57 Million USD | -1363.08% |
| 2005 Q4 | -96.57 Million USD | 17.98% |
| 2005 Q3 | -117.74 Million USD | -494.6% |
| 2005 Q2 | -19.8 Million USD | -290.05% |
| 2005 Q1 | -5.07 Million USD | 23.09% |
| 2004 Q1 | -1.16 Million USD | 82.48% |
| 2004 Q3 | -5.57 Million USD | -68.53% |
| 2004 FY | -6.6 Million USD | 0.47% |
| 2004 Q4 | -6.6 Million USD | -18.4% |
| 2004 Q2 | -3.3 Million USD | -184.68% |
| 2003 FY | -6.63 Million USD | -130.96% |
| 2003 Q1 | 17.68 Million USD | -17.42% |
| 2003 Q3 | -1.55 Million USD | 55.92% |
| 2003 Q2 | -3.53 Million USD | -119.97% |
| 2003 Q4 | -6.63 Million USD | -325.95% |
| 2002 FY | 21.41 Million USD | 1681.91% |
| 2002 Q1 | -2.4 Million USD | -77.77% |
| 2002 Q4 | 21.41 Million USD | 1419.08% |
| 2002 Q3 | 1.41 Million USD | 113.11% |
| 2002 Q2 | -10.75 Million USD | -346.82% |
| 2001 FY | -1.35 Million USD | -140.13% |
| 2001 Q2 | 9.86 Million USD | -9.78% |
| 2001 Q1 | 10.93 Million USD | 224.18% |
| 2001 Q3 | 6.4 Million USD | -35.1% |
| 2001 Q4 | -1.35 Million USD | -121.14% |
| 2000 FY | 3.37 Million USD | -67.87% |
| 2000 Q3 | -20.62 Million USD | 44.79% |
| 2000 Q2 | -37.36 Million USD | 14.05% |
| 2000 Q1 | -43.46 Million USD | -513.98% |
| 2000 Q4 | 3.37 Million USD | 116.36% |
| 1999 Q2 | -6.9 Million USD | -630.77% |
| 1999 Q1 | 1.3 Million USD | 117.57% |
| 1999 FY | 10.5 Million USD | 241.89% |
| 1999 Q4 | 10.5 Million USD | 323.4% |
| 1999 Q3 | -4.7 Million USD | 31.88% |
| 1998 Q1 | -25.1 Million USD | -1294.44% |
| 1998 Q2 | -4.8 Million USD | 80.88% |
| 1998 Q4 | -7.4 Million USD | -76.19% |
| 1998 FY | -7.4 Million USD | -311.11% |
| 1998 Q3 | -4.2 Million USD | 12.5% |
| 1997 Q2 | -7.9 Million USD | -38.6% |
| 1997 Q1 | -5.7 Million USD | 40.63% |
| 1997 FY | -1.8 Million USD | 81.25% |
| 1997 Q4 | -1.8 Million USD | 28.0% |
| 1997 Q3 | -2.5 Million USD | 68.35% |
| 1996 Q3 | -14.7 Million USD | -1030.77% |
| 1996 Q4 | -9.6 Million USD | 34.69% |
| 1996 Q1 | -5.9 Million USD | 0.0% |
| 1996 FY | -9.6 Million USD | 0.0% |
| 1996 Q2 | -1.3 Million USD | 77.97% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| uniQure N.V. | -102.95 Million USD | 114.338% |
| Agios Pharmaceuticals, Inc. | -31.21 Million USD | 147.285% |
| Amicus Therapeutics, Inc. | 198.06 Million USD | 92.547% |
| Atara Biotherapeutics, Inc. | 31.88 Million USD | 53.706% |
| bluebird bio, Inc. | 108.57 Million USD | 86.404% |
| Cara Therapeutics, Inc. | -9.01 Million USD | 263.72% |
| Imunon, Inc. | -4.69 Million USD | 414.112% |
| Editas Medicine, Inc. | -87.11 Million USD | 116.944% |
| IQVIA Holdings Inc. | 12.85 Billion USD | 99.885% |
| Mettler-Toledo International Inc. | 2.09 Billion USD | 99.296% |
| Myriad Genetics, Inc. | 88.1 Million USD | 83.245% |
| Neurocrine Biosciences, Inc. | 177.3 Million USD | 91.675% |
| Supernus Pharmaceuticals, Inc. | -33.52 Million USD | 144.027% |
| Verastem, Inc. | -37.27 Million USD | 139.597% |
| Walgreens Boots Alliance, Inc. | 8.23 Billion USD | 99.821% |
| Waters Corporation | 1.96 Billion USD | 99.247% |
| Thermo Fisher Scientific Inc. | 26.84 Billion USD | 99.945% |
| Biogen Inc. | 6.28 Billion USD | 99.765% |
| Nektar Therapeutics | 210.24 Million USD | 92.979% |
| Perrigo Company plc | 3.32 Billion USD | 99.556% |
| Dynavax Technologies Corporation | 106.63 Million USD | 86.157% |
| Illumina, Inc. | 1.21 Billion USD | 98.784% |
| Corbus Pharmaceuticals Holdings, Inc. | 6.96 Million USD | -111.838% |
| Iovance Biotherapeutics, Inc. | -113.88 Million USD | 112.961% |
| Heron Therapeutics, Inc. | 145.07 Million USD | 89.825% |
| Unity Biotechnology, Inc. | 7.18 Million USD | -105.385% |
| BioMarin Pharmaceutical Inc. | 378.74 Million USD | 96.103% |
| Sangamo Therapeutics, Inc. | -7.1 Million USD | 307.901% |
| Evolus, Inc. | 63.7 Million USD | 76.83% |
| Adicet Bio, Inc. | -142 Million USD | 110.394% |
| Aclaris Therapeutics, Inc. | -36.8 Million USD | 140.107% |
| Regeneron Pharmaceuticals, Inc. | -27.1 Million USD | 154.469% |
| Esperion Therapeutics, Inc. | 458.69 Million USD | 96.782% |
| FibroGen, Inc. | 56.76 Million USD | 73.997% |
| Agilent Technologies, Inc. | 1.14 Billion USD | 98.711% |
| OPKO Health, Inc. | 230.68 Million USD | 93.601% |
| Homology Medicines, Inc. | 18.43 Million USD | 19.938% |
| Alnylam Pharmaceuticals, Inc. | 1.58 Billion USD | 99.069% |
| Exelixis, Inc. | -73.05 Million USD | 120.207% |
| Viking Therapeutics, Inc. | -54.25 Million USD | 127.206% |
| Anavex Life Sciences Corp. | -151.02 Million USD | 109.774% |
| Intellia Therapeutics, Inc. | -111.4 Million USD | 113.25% |
| Zoetis Inc. | 4.76 Billion USD | 99.69% |
| Axsome Therapeutics, Inc. | -199.82 Million USD | 107.387% |
| Abeona Therapeutics Inc. | -10.07 Million USD | 246.569% |
| Vertex Pharmaceuticals Incorporated | -9.56 Billion USD | 100.154% |
| Kala Pharmaceuticals, Inc. | -14.57 Million USD | 201.297% |
| Ionis Pharmaceuticals, Inc. | 1.05 Billion USD | 98.6% |
| Sarepta Therapeutics, Inc. | 968.37 Million USD | 98.476% |
| Corcept Therapeutics Incorporated | -135.4 Million USD | 110.902% |
| Halozyme Therapeutics, Inc. | 1.38 Billion USD | 98.931% |
| Blueprint Medicines Corporation | 702.83 Million USD | 97.9% |
| Insmed Incorporated | 721.62 Million USD | 97.954% |
| TG Therapeutics, Inc. | 17.86 Million USD | 17.361% |
| Incyte Corporation | -3.17 Billion USD | 100.465% |
| Emergent BioSolutions Inc. | 765.8 Million USD | 98.072% |